UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/825,593	04/16/2004	Nicholas Barden	028622-0130	7794	
	7590 07/11/200 LARDNER LLP	EXAMINER			
SUITE 500	T NIVI	PAK, MICHAEL D			
3000 K STREE WASHINGTO			ART UNIT	PAPER NUMBER	
			1646		
			MAIL DATE	DELIVERY MODE	
			07/11/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)	
Office Action Summary		10/825,593	BARDEN ET AL.	
		Examiner	Art Unit	
		Michael Pak	1646	
The MAILING DATE of this Period for Reply	communication app	ears on the cover sheet wit	h the correspondence ac	idress
A SHORTENED STATUTORY PE WHICHEVER IS LONGER, FROM - Extensions of time may be available under the after SIX (6) MONTHS from the mailing date - If NO period for reply is specified above, the - Failure to reply within the set or extended per Any reply received by the Office later than the earned patent term adjustment. See 37 CFR	A THE MAILING DA e provisions of 37 CFR 1.13 of this communication. maximum statutory period w iod for reply will, by statute, ee months after the mailing	TE OF THIS COMMUNIC 6(a). In no event, however, may a re ill apply and will expire SIX (6) MONT cause the application to become ABA	ATION. ply be timely filed HS from the mailing date of this of the condition of the condit	·
Status				
 1) ☐ Responsive to communicat 2a) ☐ This action is FINAL. 3) ☐ Since this application is in colosed in accordance with the 	2b)∭ This ondition for allowar	action is non-final. ce except for formal matte	•	e merits is
Disposition of Claims				
4) ☐ Claim(s) <u>1-22,24-30,32-34 and the sequence of the above claim(s) 1-5</u> ☐ Claim(s) is/are allow 6) ☐ Claim(s) <u>36-37, 39-43 is/are object and the sequence of the s</u>	22,24-30,32-34,38 ed. e rejected. ted to.	<u>and 44-56</u> is/are withdrawi	n from consideration.	
Application Papers				
9) The specification is objected 10) The drawing(s) filed on Applicant may not request that Replacement drawing sheet(s) 11) The oath or declaration is ob	_ is/are: a) ☐ acce any objection to the c including the correcti	epted or b) objected to b drawing(s) be held in abeyand on is required if the drawing(s	ce. See 37 CFR 1.85(a). s) is objected to. See 37 C	• •
Priority under 35 U.S.C. § 119				
2. Certified copies of the	one of: e priority documents priority documents copies of the prior nternational Bureau	s have been received. s have been received in Ap ity documents have been i (PCT Rule 17.2(a)).	oplication No received in this National	Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing 3) Information Disclosure Statement(s) (PT Paper No(s)/Mail Date <u>4-4-08</u> .		Paper No(s)	ummary (PTO-413) /Mail Date formal Patent Application _·	

10/825,593 Art Unit: 1646

DETAILED ACTION

Response to Amendment

- 1. Amendment filed April 4, 2008 has been entered.
- 2. Applicant's arguments filed April 4, 2008, have been fully considered but they are not found persuasive.
- 3. Claims 36-37 and 39-43 are examined below. Claims 1-22, 24-30, 32-34, 38, and 44-56 are withdrawn. Claims 23, 31, and 35 are cancelled.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 4. Claims 36-37 and 39-43 are rejected under 35 U.S.C. 102(b) as being anticipated by McElroy (US 6,323,236).

McElroy teach a method of administering tenidap for treatment of major depression (column1, lines 45-55; column 8, line 35). The administration of beta-

Art Unit: 1646

adrenergic receptor modulator is optional. Tenidap inherently treats major depression when administered and modulates P2X7R activity.

Applicants argue that ICD treatment of McElroy is separate from the major depression as shown by DSM-IV-TR. However, McElroy specifically state that ICDs may be related to mood disorder or may be forms of affective spectrum disorder, a hypothesized family of disorders sharing at least one common physiologic abnormality with major depression (column 1, lines 45-49). Thus, McElroy clearly intends to teach treatment of major depression.

Applicants argue that sulfamates of McElroy is different from the claimed Tenidap. However, McElroy teach the adminstration of tenidap along with sulfamates (column 8, line 35). Thus McElroy teach treatment with tenidap which inherently is a modulator of P2X7R.

Applicants argue that McElroy use tenidap only as an anti-inflammatory drugs to be used in combination with sulfamates and thus is not used to treat major depression. However, McElroy teach treatment of major depression because McElroy teach that ICDs are form of major depression and McElroy teach adminstration of tenidap. Thus, McElroy teach adminstration of tenidap to treat major depression. Tenidap inherently is a modulator of P2X7R.

5. No claim is allowed.

Art Unit: 1646

6. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak whose telephone number is 571-272-0879. The examiner can normally be reached on 8:00 - 2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/825,593 Art Unit: 1646

Page 5